The Food and Drug Administration yesterday issued a streamlined form for physicians to request expanded access to investigational drugs and biologics for patients with serious or immediately life-threatening diseases and no comparable or satisfactory alternative therapy. The agency also issued instructions for completing the form, and guidance on when and how to request expanded access and how patients may be charged for investigational drugs. “The FDA has a long history of supporting patient access to investigational treatments and we hope the information released today will help health care professionals, patients and industry to more easily navigate the expanded access process and help patients who qualify to gain access to potentially life-saving investigational treatments,” said FDA Commissioner Robert Califf, M.D.

Related News Articles

Headline
The departments of Health and Human Services and the Treasury today approved a Section 1332 waiver for Oregon to implement a five-year reinsurance…
Headline
President Trump today issued an executive order directing the departments of Treasury, Labor and Health and Human Services to consider proposing regulations or…
Headline
More than 880,000 physicians were certified by the American Board of Medical Specialties in 2017, about 20,000 more than in 2016, according to the board’…
Headline
The Centers for Medicare & Medicaid Services has identified the first clinicians eligible to participate in 2018 advanced alternative payment models, based…
Headline
The National Collaborative for Improving the Clinical Learning Environment this week released guidance to help health care system leaders work with clinical…
Headline
In a letter this week, the AHA again urged the Centers for Medicare & Medicaid Services to take specific actions to address and prevent the serious…